Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Tag
prostate
AI biomarker substantially reduced planned ADT use in intermediate-risk prostate cancer
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.
Rectal spacer geometry remained stable throughout five-fraction prostate SBRT
Hydrogel spacers showed no meaningful loss of geometry during prostate SBRT, supporting stable rectal separation across the treatment course.
Prostate target expansion identified fractions most likely to benefit from online re-optimization
Without online re-optimization, 65.3% of prostate fractions missed 95% target coverage, with later target expansion strongly linked to coverage loss.
Deep learning-enhanced registration halves contouring time in daily adaptive prostate MRgRT
A hybrid deep learning–registration workflow reduced median daily prostate MRgRT contouring time from 7.8 to 3.1 minutes while maintaining high contour agreement.
LncDNAH5 linked a prostate radiotoxicity risk variant to altered DNA repair
The rs7720298 risk allele increased LncDNAH5 expression, promoting TP53BP1 degradation and worsening radiation-induced bladder injury in mice.
Empty-bladder prostate SBRT met the EMPTY-RT acute safety endpoint
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
Patient-informed design supported rapid and representative COMPPARE trial accrual
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Experts reached limited consensus on prostate GTV contouring and micro-boosting
Only 33% of statements reached consensus, but experts agreed on multimodality imaging, eligible lesions, and daily image guidance.
Adaptive MR-guided prostate SBRT showed low toxicity after the early treatment peak
Grade ≥2 urinary toxicity fell from 22% at two weeks to 3% at six months, with almost no clinically significant bowel toxicity.
Prostate radiotherapy biomarker review found timing more limiting than assay choice
None of four selected blood-biomarker domains currently supports treatment personalization, and sampling schedules frequently failed to match expected biological kinetics.
Virtual reality increased confidence after HDR prostate brachytherapy training
Brief virtual-reality training increased self-reported procedural confidence, but knowledge, technical skill, retention, and clinical performance were not tested.
Five-fraction MR-guided prostate-bed radiotherapy showed low early toxicity
No grade 3 toxicity occurred after five-fraction MR-guided salvage radiotherapy, while urinary and bowel quality-of-life scores remained stable.
Prostate radiotherapy modestly increased secondary pelvic cancer incidence over long follow-up
Randomized evidence suggested a 4.5-point increase in second-cancer incidence, while excess mortality from other cancers was substantially smaller.
AutoAdapt produced acceptable prostate MR-guided plans with minimal planner input
AI-generated constraints produced clinically acceptable adaptive prostate plans, although only seven of ten met every prespecified planning objective.